Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 59HER2-positive Breast Cancer 14Carcinoma, Non-Small-Cell Lung 5Breast Diseases 4Brain Neoplasms 3Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2HER2-positive Metastatic Breast Cancer 2Colorectal Neoplasms 2Breast Cancer Invasive 2Breast Cancer Female 2Advanced Breast Cancer 2Stomach Neoplasms 1Solid Tumor 1Rare Tumour 1Rare Tumor 1Pathologic Complete Response 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Lung Neoplasms 1Locally Advanced Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-positive Advanced Breast Cancer 1HER2+ Early or Locally Advanced Breast Cancer 1HER2+ Breast Cancer 1HER2 Positive Breast Cancer 1HER2 Insertion Mutation Positive Advanced NSCLC 1HER-2 Positive Colorectal Cancer 1Estrogen Receptor-positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1

Interventions

pyrotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER2 Insertion Mutation Positive Advanced NSCLC × pyrotinib × Clear all
NCT04144569 2024-09-19

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

Hunan Province Tumor Hospital

Phase 2 Recruiting
30 enrolled
Thoracic

HER2 Insertion Mutation Positive Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡